GMPs have been found to be increased across a variety of tumor types in previous studies.20 Poorer clinical outcomes were associated with higher circulating GMPs, as reflected by clinical stages and reduced time to progression.20 Consistent with this process is our observation that GMPs in CCL20-overexpressing cell allograft mouse model were remarkably increased. This evidence concerns the gene CCL20 and neoplasm.